Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Danø

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
Ugeskrift for Laeger|July 27, 2001
[New basis for development of anticancer drugs]K Danø
Cancer Chemotherapy Reports|June 1, 1972
Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivoK Danø
FEBS Letters|February 3, 1997
Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi)N Behrendt, K Danø
Enzyme & Protein|January 1, 1996
Stromal cell expression of components of matrix-degrading protease systems in human cancerR Hewitt, K Danø
The Biochemical Journal|December 1, 1993
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suraminV Ellis, K Danø
FEBS Letters|September 9, 1996
Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation systemN Behrendt, K Danø
Biochimica Et Biophysica Acta|January 12, 1979
Plasminogen activator from cells transformed by an oncogenic virus: inhibitors of the activation reactionK Danø, E Reich
The Journal of Experimental Medicine|March 1, 1978
Serine enzymes released by cultured neoplastic cellsK Danø, E Reich
Ugeskrift for Laeger|August 24, 1981
[Carcinogenesis and drugs]K Danø, J Forchhammer
The Journal of Biological Chemistry|March 5, 1993
Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activationV Ellis, K Danø
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
Ugeskrift for Laeger|July 27, 2001
[New basis for development of anticancer drugs]K Danø
Cancer Chemotherapy Reports|June 1, 1972
Development of resistance to adriamycin (NSC-123127) in Ehrlich ascites tumor in vivoK Danø
FEBS Letters|February 3, 1997
Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi)N Behrendt, K Danø
Enzyme & Protein|January 1, 1996
Stromal cell expression of components of matrix-degrading protease systems in human cancerR Hewitt, K Danø
The Biochemical Journal|December 1, 1993
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suraminV Ellis, K Danø
FEBS Letters|September 9, 1996
Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation systemN Behrendt, K Danø
Biochimica Et Biophysica Acta|January 12, 1979
Plasminogen activator from cells transformed by an oncogenic virus: inhibitors of the activation reactionK Danø, E Reich
The Journal of Experimental Medicine|March 1, 1978
Serine enzymes released by cultured neoplastic cellsK Danø, E Reich
Ugeskrift for Laeger|August 24, 1981
[Carcinogenesis and drugs]K Danø, J Forchhammer
The Journal of Biological Chemistry|March 5, 1993
Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activationV Ellis, K Danø
Pageof 17